Rate of and Response to Dose Escalation in Patients Treated With Adalimumab for Moderately-to-Severely Active Ulcerative Colitis: ULTRA 2 Subanalysis

被引：1
|
作者：
Wolf, Doug [1 ]
D'Haens, Geert [2 ,3 ]
Sandborn, William [4 ]
Colombel, Jean-Frederic [5 ]
Van Assche, Gert [6 ]
Lazar, Andreas [7 ]
Zhou, Qian [8 ]
Robinson, Anne [8 ]
Chao, Jingdong [8 ]
Thakkar, Roopal [8 ]
机构：
[1] Atlanta Gastroenterol Associates, Atlanta, GA USA
[2] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[3] Imelda GI Clin Res Ctr, Amsterdam, Netherlands
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
[5] CHRU, Hop Huriez, Lille, Nord, France
[6] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[7] Abbott GmbH & Co KG, Ludwigshafen, Germany
[8] Abbott, Abbott Pk, IL USA
来源：
INFLAMMATORY BOWEL DISEASES | 2012年 / 18卷
关键词：
D O I：
10.1097/00054725-201212001-00055
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [1] Rate of and Response to Dose Escalation in Patients Treated With Adalimumab for Moderately to Severely Active Ulcerative Colitis: Subanalysis of ULTRA 2
    Wolf, Douglas
    D'Haens, Geert
    Sandborn, William
    Colombel, Jean-Frederic
    Van Assche, Gert
    Lazar, Andreas
    Zhou, Qian
    Robinson, Anne
    Chao, Jingdong
    Thakkar, Roopal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S619 - S619
  • [2] Effect of Adalimumab Dose Escalation on Hospitalization Risk in Patients With Moderately to Severely Active Ulcerative Colitis
    Feagan, Brian
    Skup, Martha
    Thakkar, Roopal
    Lazar, Andreas
    Yang, Min
    Macaulay, Dendy
    Chao, Jingdong
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S768 - S768
  • [3] Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis
    Wolf, D.
    D'Haens, G.
    Sandborn, W. J.
    Colombel, J. -F.
    Van Assche, G.
    Robinson, A. M.
    Lazar, A.
    Zhou, Q.
    Petersson, J.
    Thakkar, R. B.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (05) : 486 - 497
  • [4] Time to Remission and Response in Adalimumab-treated Patients with Moderately to Severely Active Ulcerative Colitis from ULTRA 2
    Colombel, Jean-Frederic
    Plevy, Scott
    Sandborn, William
    D'Haens, Geert
    Robinson, Anne
    Petersson, J.
    Huang, Bidan
    Lazar, Andreas
    Thakkar, Roopal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S505 - S505
  • [5] Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis
    Kassir, Nastya
    Zhu, Rui
    Moein, Anita
    Langenhorst, Jurgen
    Ribbing, Jakob
    Zhang, Rong
    Tang, Meina T.
    Oh, Young S.
    Zhang, Wenhui
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1234 - 1243
  • [6] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
  • [7] Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis
    Moein, Anita
    Lu, Tong
    Jonsson, Siv
    Ribbing, Jakob
    Kassir, Nastya
    Zhang, Wenhui
    Sperinde, Gizette
    Zhang, Rong
    Tang, Meina
    Oh, Young S.
    Bruno, Rene
    Zhu, Rui
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1244 - 1255
  • [8] Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis
    Toor, Kabirraaj
    Druyts, Eric
    Jansen, Jeroen P.
    Thorlund, Kristian
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (06) : 437 - 446
  • [9] The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
    Shin, S. Shin
    Park, S. J.
    Kim, Y.
    Im, J. P.
    Kim, H. J.
    Lee, K. M.
    Kim, J. W.
    Jung, S. A.
    Lee, J.
    Kang, S. B.
    Shin, S. J.
    Kim, E. S.
    Kim, Y. S.
    Kim, T. O.
    Kim, H. S.
    Park, D. I.
    Kim, H. K.
    Kim, E. S.
    Kim, Y. H.
    Kim, D. H.
    Teng, D.
    Kim, J. H.
    Kim, W. Y.
    Choi, C. H.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S432 - S432
  • [10] Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Keohane, A.
    Zhu, B.
    Ritter, T.
    Regueiro, M.
    Hudesman, D.
    Chen, Y. F.
    Owen, C.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1975 - I1976
12345